ROIV — Roivant Sciences Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1635088 ·
United Kingdom
Last close
$35.80
Market Cap
$25.86B
52W High
$42.50
52W Low
$14.86
ADV30
9,035,413
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,442,000 | 1,158,000 | -366,385,000 | -189,837,000 | 5,306,493,000 | 1,248,456,000 | 384,624,000 |
| Mar 2026 | 2,520,000 | 2,200,000 | -354,995,000 | 302,994,000 | 5,708,687,000 | 1,419,232,000 | 416,275,000 |
| Dec 2025 | 1,999,000 | 1,299,000 | -339,153,000 | -265,891,000 | 5,225,368,000 | 1,478,270,000 | 251,144,000 |
| Sep 2025 | 1,571,000 | 1,460,000 | -306,233,000 | -113,519,000 | 5,062,598,000 | 1,237,010,000 | 257,140,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-816,470,000
Investing CF
$684,643,000
Financing CF
$140,494,000
CapEx
$-13,563,000
Dividends Paid
—
Buybacks
$-317,939,000
EPS Diluted TTM
$-0.53
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-900,354,000
Inventory
—
Receivables
$771,627,000
ST Investments
$2,593,626,000
EBIT TTM
$-1,366,766,000
Pretax Income TTM
$-289,880,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,532,000
EBITDA
$-1,360,626,944
Free Cash Flow
$-1,127,230,080
Enterprise Value
$26,440,892,416
Total Cash
$3,842,082,048
Total Debt
$107,152,000
Shares Out
722,323,015
Trailing EPS
$-0.47
Book Value
$5.86
ROE
-8.5%
ROA
-16.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,260,000 | -1,285,303,000 | -299,771,000 | 5,708,687,000 | 416,275,000 | 4,527,370,000 | -750,349,000 |
| Mar 2025 | 29,053,000 | -1,113,681,000 | -171,981,000 | 5,436,940,000 | 249,742,000 | 4,687,605,000 | -839,451,000 |
| Mar 2024 | 32,713,000 | -824,928,000 | 4,348,926,000 | 7,222,482,000 | 773,953,000 | 5,968,581,000 | -765,268,000 |
| Mar 2023 | 31,530,000 | -809,014,000 | -1,009,030,000 | 2,389,604,000 | 782,017,000 | 1,157,766,000 | -843,393,000 |
TTM Snapshot
Revenues TTM
$9,018,000
NetIncome TTM
$169,381,000
OpCashFlow TTM
$0
Assets (Latest)
$5,436,940,000
Forward EPS
$-1.72
Max Pain — expiry 2026-12-18
max pain strike: $39.00 · spot: $37.09 · call oi: 20,694 · put oi: 12,821Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RPRX | Royalty Pharma plc | $25.92B | $58.21 | — |
| INSM | INSMED Inc | $25.73B | $117.83 | — |
| ZTS | Zoetis Inc. | $29.36B | $71.05 | — |
| GMAB | GENMAB A/S | $21.72B | $35.32 | — |
| VTRS | Viatris Inc | $20.48B | $17.83 | — |
News headlines (Yahoo Finance, 1h cache)
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
2026-09-28 08:02 · Yahoo
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
2026-09-24 17:02 · Yahoo
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
2026-09-23 12:12 · Yahoo
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
2026-09-22 10:27 · Yahoo
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
2026-09-18 11:15 · Yahoo
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
2026-09-13 09:45 · Yahoo
Company News for Sep 9, 2026
2026-09-09 11:15 · Yahoo
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%
2026-09-09 01:40 · Yahoo
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
2026-09-08 17:53 · Yahoo
Top Midday Gainers
2026-09-08 17:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.